NewsBenzinga오펜하이머, 아틀라시안에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 240달러로 하향 오펜하이머, 아틀라시안에 대한 ‘시장수익률 상회’ 의견 유지···목표주가 240달러로 하향 Benzinga 2026.11.06 17:12 (GMT+0) Open on Benzinga Other news Canaccord Genuity Maintains Buy on Redwire, Lowers Price Target to $13 RBC Capital Maintains Outperform on Verastem, Lowers Price Target to $18 Canaccord Genuity Maintains Buy on NuScale Power, Lowers Price Target to $11 RBC Capital Maintains Outperform on Veeva Systems, Raises Price Target to $365 Canaccord Genuity Maintains Buy on TransMedics Group, Raises Price Target to $120 RBC Capital Maintains Outperform on VSE, Raises Price Target to $225
